NASDAQ:ALEC Alector (ALEC) Stock Price, News & Analysis $1.56 -0.05 (-2.80%) As of 11:48 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Alector Stock (NASDAQ:ALEC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Alector alerts:Sign Up Key Stats Today's Range$1.54▼$1.6150-Day Range$1.48▼$2.5752-Week Range$1.09▼$3.40Volume158,683 shsAverage Volume802,595 shsMarket Capitalization$173.75 millionP/E RatioN/ADividend YieldN/APrice Target$3.63Consensus RatingHold Company Overview Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia. The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies. Alector designs its molecules to engage key immune receptors in the brain, seeking to slow or halt disease progression rather than simply address symptoms. Research and development activities are supported by state-of-the-art laboratories in North America and collaborations with academic and industry partners in Europe. Since completing its initial public offering in 2019, Alector has expanded its clinical footprint through strategic alliances and investigator-initiated trials. The company maintains global development programs aimed at bringing the first approved immuno-neurology therapies to patients worldwide. Alector is led by co-founder and Chief Executive Officer Dr. Arnon Rosenthal, a neuroscientist with over two decades of experience in immunology and drug discovery. The management team brings extensive backgrounds in clinical development, regulatory affairs, and commercialization, supporting Alector’s mission to transform the treatment landscape for neurodegenerative diseases.AI Generated. May Contain Errors. Read More Alector Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreALEC MarketRank™: Alector scored higher than 49% of companies evaluated by MarketBeat, and ranked 544th out of 853 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingHold Consensus RatingAlector has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on no strong buy ratings, 3 buy ratings, 3 hold ratings, and 2 sell ratings.Upside PotentialAlector has a consensus price target of $3.63, representing about 127.3% upside from its current price of $1.60.Amount of Analyst CoverageAlector has only been the subject of 3 research reports in the past 90 days.Read more about Alector's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Alector are expected to grow in the coming year, from ($0.86) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alector is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alector is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlector has a P/B Ratio of 5.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alector's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.61% of the float of Alector has been sold short.Short Interest Ratio / Days to CoverAlector has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Alector has recently increased by 8.93%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlector does not currently pay a dividend.Dividend GrowthAlector does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.11 News SentimentAlector has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Alector this week, compared to 4 articles on an average week.Search Interest4 people have searched for ALEC on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Alector to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Alector insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $232,557.00 in company stock.Percentage Held by Insiders8.30% of the stock of Alector is held by insiders.Percentage Held by Institutions85.83% of the stock of Alector is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alector's insider trading history. Receive ALEC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALEC Stock News HeadlinesGSK ends brain drug alliance with AlectorJuly 9, 2026 | finance.yahoo.comAlector stock plummets 13% as GSK terminates neuroscience pactJuly 9, 2026 | msn.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.July 13 at 1:00 AM | Porter & Company (Ad)Alector and GSK partnership to end after dementia, Alzheimer's drug failuresJuly 8, 2026 | reuters.comAlector (ALEC) Stock Faces Mixed Analyst Target Changes On Tau Therapy ReadthroughJune 19, 2026 | finance.yahoo.comAlector Shareholders Back Directors, Auditor and Executive PayJune 17, 2026 | tipranks.comAlector Establishes $125 Million At-the-Market OfferingMay 10, 2026 | theglobeandmail.comAlector Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 7, 2026 | globenewswire.comSee More Headlines ALEC Stock Analysis - Frequently Asked Questions How have ALEC shares performed this year? Alector's stock was trading at $1.56 at the beginning of 2026. Since then, ALEC shares have increased by 2.2% and is now trading at $1.5950. How were Alector's earnings last quarter? Alector, Inc. (NASDAQ:ALEC) announced its earnings results on Thursday, May, 7th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.08. The firm earned $1.05 million during the quarter, compared to analysts' expectations of $9.67 million. Alector had a negative trailing twelve-month return on equity of 295.17% and a negative net margin of 680.83%. Does Alector have any subsidiaries? The following companies are subsidiaries of Alector: Alector LLC. When did Alector IPO? Alector (ALEC) raised $176 million in an IPO on Thursday, February 7th 2019. The company issued 9,250,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO. How do I buy shares of Alector? Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alector own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alector investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Enovix (ENVX), Meta Platforms (META), Rambus (RMBS), Saia (SAIA) and Tesla (TSLA). Company Calendar Last Earnings5/07/2026Today7/13/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4d) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 As of 4 days ago, ALEC's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALEC CIK1653087 Webwww.alector.com Phone(415) 231-5660FaxN/AEmployees270Year Founded2013Price Target and Rating Average Price Target for Alector$3.63 High Price Target$6.00 Low Price Target$1.50 Potential Upside/Downside+133.1%Consensus RatingHold Rating Score (0-4)2.13 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$142.93 million Net Margins-680.83% Pretax Margin-679.91% Return on Equity-295.17% Return on Assets-40.95% Debt Debt-to-Equity Ratio0.80 Current Ratio5.25 Quick Ratio5.25 Sales & Book Value Annual Sales$18.42 million Price / Sales9.37 Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book5.55Miscellaneous Outstanding Shares111,025,000Free Float101,810,000Market Cap$172.64 million OptionableOptionable Beta0.60 Social Links 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:ALEC) was last updated on 7/13/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alector With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
